Back to Stocks

TRVI

Trevi Therapeutics, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Trevi Therapeutics has transitioned into a well-capitalized pivotal-stage developer, backed by a massive $162 million net capital raise in April 2026.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the recent capital infusion, concerns persist regarding Trevi's accelerating cash burn. Operating cash consumption rose to $16.7 million in the first quarter of 2026, a 24% increase year-over-year, driven by rising R&D and G&A expenses.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every TRVI filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company at a critical inflection point, balancing a strong clinical signal against a high-burn financial model. The successful April 2026 offering at $13.00 per share demonstrates strong institutional support and provides the necessary fuel for the upcoming Phase 3 trials. However, the widening net loss to $13.2 million highlights the inherent costs of advancing a drug candidate through the most expensive stages of development. Ultimately, the investment thesis now shifts from a question of survival to a question of clinical execution. With a fortified balance sheet, the primary catalyst is no longer the ability to raise money, but the ability to successfully navigate the pivotal trials for IPF and RCC. Investors must weigh the high potential reward of a first-in-class chronic cough therapy against the binary risk of Phase 3 outcomes and the potential for long-term warrant dilution.

Selected Quarter

Core Takeaway

Trevi has secured enough liquidity to fund its primary Phase 3 IPF trials, shifting the risk profile from financial solvency to clinical execution.

Investor Lens

The trade-off is between the high-conviction Phase 2 data and the binary risk of Phase 3 results combined with warrant overhang.

Watch Next

Initiation of the first Phase 3 trial for IPF-related chronic cough in Q2 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.33Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 5

Raised approximately $162 million net in April 2026 to fund Phase 3 trials.

capital raise
90%
bearishMay 5

Net loss widened to $13.2 million as R&D and G&A expenses increased year-over-year.

margin compression
60%
bullishMay 5

FDA alignment reached for two pivotal Phase 3 trials for IPF-related chronic cough.

guidance raise
70%
bullishMay 5

Raised approximately $162 million net in April 2026 to fund Phase 3 trials.

capital raise
90%
bearishMay 5

Net loss widened to $13.2 million as R&D and G&A expenses increased year-over-year.

margin compression
60%
bullishMay 5

FDA alignment reached for two pivotal Phase 3 trials for IPF-related chronic cough.

guidance raise
70%
bullishMay 5

Raised approximately $162 million net in April 2026 to fund Phase 3 trials.

capital raise
90%
bearishMay 5

Net loss widened to $13.2 million as R&D and G&A expenses increased year-over-year.

margin compression
60%
bullishMay 5

FDA alignment reached for two pivotal Phase 3 trials for IPF-related chronic cough.

guidance raise
70%
bullishMay 5

Raised approximately $162 million net in April 2026 to fund Phase 3 trials.

capital raise
90%
bearishMay 5

Net loss widened to $13.2 million as R&D and G&A expenses increased year-over-year.

margin compression
60%
bullishMay 5

FDA alignment reached for two pivotal Phase 3 trials for IPF-related chronic cough.

guidance raise
70%
bullishMay 5

Raised approximately $162 million net in April 2026 to fund Phase 3 trials.

capital raise
90%
bearishMay 5

Net loss widened to $13.2 million as R&D and G&A expenses increased year-over-year.

margin compression
60%
bullishMay 5

FDA alignment reached for two pivotal Phase 3 trials for IPF-related chronic cough.

guidance raise
70%
bullishMay 5

Raised approximately $162 million net in April 2026 to fund Phase 3 trials.

capital raise
90%
bearishMay 5

Net loss widened to $13.2 million as R&D and G&A expenses increased year-over-year.

margin compression
60%
bullishMay 5

FDA alignment reached for two pivotal Phase 3 trials for IPF-related chronic cough.

guidance raise
70%
bullishMay 5

Raised approximately $162 million net in April 2026 to fund Phase 3 trials.

capital raise
90%
bearishMay 5

Net loss widened to $13.2 million as R&D and G&A expenses increased year-over-year.

margin compression
60%
bullishMay 5

FDA alignment reached for two pivotal Phase 3 trials for IPF-related chronic cough.

guidance raise
70%

Filing History

10-QMay 5, 2026
Expand Sequence

The Q1 2026 filing reveals a company at a critical inflection point, balancing a strong clinical signal against a high-burn financial model. The successful April 2026 offering at $13.00 per share demonstrates strong institutional support and provides the necessary fuel for the upcoming Phase 3 trials. However, the widening net loss to $13.2 million highlights the inherent costs of advancing a drug candidate through the most expensive stages of development. Ultimately, the investment thesis now shifts from a question of survival to a question of clinical execution. With a fortified balance sheet, the primary catalyst is no longer the ability to raise money, but the ability to successfully navigate the pivotal trials for IPF and RCC. Investors must weigh the high potential reward of a first-in-class chronic cough therapy against the binary risk of Phase 3 outcomes and the potential for long-term warrant dilution.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.